Industrial Automation Validation and Testing Services

Validation and testing services occupy a critical checkpoint between the design and deployment of industrial automation systems, ensuring that equipment, software, and integrated processes perform to documented specifications before production begins. This page covers the definitions, procedural structure, common application scenarios, and decision criteria that govern how validation and testing are scoped and executed across manufacturing and process industries in the United States. Failure to validate automated systems is a documented root cause of regulatory non-compliance, production loss, and safety incidents — making these services a non-negotiable component of responsible automation lifecycle management. The scope spans discrete manufacturing, continuous process industries, pharmaceutical production, food and beverage, and energy sectors.

Definition and scope

Industrial automation validation confirms that a system — whether a programmable logic controller (PLC), a robotic cell, a SCADA platform, or an integrated manufacturing execution system — does what it is designed to do, consistently, under defined operating conditions. Testing is the broader category of activities that generate objective evidence; validation is the formal conclusion drawn from that evidence.

The distinction matters in regulated industries. The U.S. Food and Drug Administration's 21 CFR Part 11 and 21 CFR Part 820 require documented validation of software and automated systems used in medical device and pharmaceutical manufacturing. Outside FDA-regulated environments, standards such as ISA-88 (batch control) and ISA-99/IEC 62443 (industrial cybersecurity) define validation requirements for process automation and control system security respectively.

Scope boundaries typically include:

1. Hardware qualification — physical components, wiring, and instrument ranges
2. Software verification — PLC/DCS logic, HMI screens, and recipe management
3. Integration testing — communication between subsystems (e.g., MES-to-PLC data exchange)
4. Performance testing — throughput, cycle time, and fault recovery under load
5. Safety function testing — verification of safety-instrumented system (SIS) responses per IEC 61511

For context on how validation fits within the broader service landscape, the types of industrial automation services page provides a classification framework.

How it works

Validation and testing engagements follow a structured lifecycle derived from the V-Model, which pairs each design stage with a corresponding test stage. The phases below reflect common industry practice aligned with GAMP 5 (Good Automated Manufacturing Practice), published by the International Society for Pharmaceutical Engineering (ISPE).

Phase 1 — Validation Planning
A Validation Master Plan (VMP) defines scope, responsibilities, acceptance criteria, and the regulatory framework applicable to the project. This document is produced before any testing begins and is reviewed by quality assurance personnel.

Phase 2 — Design Qualification (DQ)
Evidence is collected to confirm that the system design meets user requirements and applicable standards. This phase occurs before equipment is procured or built.

Phase 3 — Installation Qualification (IQ)
After installation, IQ confirms that hardware and software are installed correctly per manufacturer specifications and the approved design. Instrument calibration records, wiring diagrams, and software version logs are captured here.

Phase 4 — Operational Qualification (OQ)
OQ tests that the system operates within specified ranges under simulated or actual process conditions, including boundary and worst-case scenarios. Alarm responses, interlock functions, and failure modes are exercised.

Phase 5 — Performance Qualification (PQ)
PQ demonstrates consistent performance under actual production conditions over a defined number of runs or time period. In pharmaceutical applications, PQ often requires a minimum of 3 consecutive successful batches (ISPE GAMP 5).

Phase 6 — Validation Summary Report
All test results, deviations, and corrective actions are compiled. The system is released for production only after formal sign-off.

Providers specializing in industrial automation commissioning services frequently execute IQ and OQ phases, while industrial automation engineering services teams typically own DQ documentation and PQ protocol design.

Common scenarios

Pharmaceutical and biotech manufacturing — FDA 21 CFR Part 11 mandates electronic record and audit trail validation for any computerized system that creates, modifies, or transmits data used in regulatory submissions. A single 483 observation related to inadequate computer system validation can delay product release.

Automotive assembly robotics — Robotic welding and assembly cells undergo cycle-time testing, repeatability measurement (commonly ±0.05 mm tolerance verification for high-precision joints), and safety zone validation per ISO 10218-1/2 before line release.

Food and beverage — CIP/SIP systems — Clean-in-place and sterilize-in-place systems require temperature, flow, and contact-time validation to satisfy FDA and USDA sanitation requirements. Temperature uniformity testing typically maps 12 or more data logger positions within a sterilization chamber.

Energy and utilities — SCADA and DCS upgrades — When a SCADA platform is upgraded or migrated, regression testing confirms that all control logic, setpoints, and alarm configurations carry over accurately. An undocumented logic change in a legacy migration is a cited cause of process upsets.

Safety system revalidation — Any modification to a safety-instrumented function (SIF) triggers revalidation under IEC 61511, including recalculation of the Safety Integrity Level (SIL) and proof-test interval.

Decision boundaries

When full IQ/OQ/PQ is required vs. when abbreviated testing suffices: Regulated industries (pharmaceutical, medical device, food, nuclear) require the full qualification sequence with formal documentation. Discrete manufacturing without regulatory drivers may apply risk-based testing scoped to critical functions only.

Validation vs. commissioning: Commissioning confirms mechanical and electrical completion; validation confirms functional and performance compliance to specifications. The two activities overlap in the IQ phase but serve different purposes. Commissioning without subsequent validation is insufficient for regulated applications. See industrial automation commissioning services for the commissioning-specific framework.

Internal execution vs. third-party validation: Third-party validation providers are required in GxP environments where the quality unit demands independence between the system builder and the validator. In non-regulated environments, the engineering team that built the system may execute testing internally, provided documented protocols and acceptance criteria are established in advance.

Revalidation triggers: System changes that alter validated state — hardware replacements with different specifications, software version upgrades, process parameter changes outside validated ranges, or facility moves — require formal change control and revalidation scoped to the affected functions. Not all changes require full requalification; a documented impact assessment determines scope, per ISPE GAMP 5 guidance.

For procurement considerations when sourcing these services, the industrial automation service procurement process page outlines evaluation criteria and contracting structures.

References

• FDA 21 CFR Part 11 — Electronic Records; Electronic Signatures
• FDA 21 CFR Part 820 — Quality System Regulation (Medical Devices)
• ISA-88 Batch Control Standard — ISA
• ISA-99 / IEC 62443 Industrial Cybersecurity — ISA
• ISA-84 / IEC 61511 Safety Instrumented Systems — ISA
• ISPE GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems, 2nd Edition — ISPE
• ISO 10218-1:2011 — Robots and Robotic Devices, Safety Requirements for Industrial Robots
• NIST SP 800-82 Rev 3 — Guide to OT Security (NIST)